N-(2-HYDROXYPROPYL)METHACRYLAMIDE manufacturers
|
| | N-(2-HYDROXYPROPYL)METHACRYLAMIDE Basic information |
| Product Name: | N-(2-HYDROXYPROPYL)METHACRYLAMIDE | | Synonyms: | N-(2-HYDROXYPROPYL)METHACRYLAMIDE;N-(2-Hydroxypropyl)-2-methyl-prop-2-enamide;N-(2-Hydroxypropyl)-2-methyl-prop-2-enamide AldrichCPR;2-Hydroxypropyl methacrylamide 99% (GC);2-Hydroxypropyl methacrylamide;2-Propenamide,N-(2-hydroxypropyl)-2-methyl-;N-(2-HYDROXYPROPYL)METHACRYLAMID;High purity CAS 21442-01-3 N-(2-HYDROXYPROPYL)METHACRYLAMIDE in stock | | CAS: | 21442-01-3 | | MF: | C7H13NO2 | | MW: | 143.18 | | EINECS: | | | Product Categories: | monomer | | Mol File: | 21442-01-3.mol |  |
| | N-(2-HYDROXYPROPYL)METHACRYLAMIDE Chemical Properties |
| Melting point | 67.92°C | | Boiling point | 321.2±34.0 °C(Predicted) | | density | 1.002 g/mL ((predicted)) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO | | form | powder | | pka | 14.43±0.20(Predicted) | | color | White to off-white | | InChI | 1S/C7H13NO2/c1-5(2)7(10)8-4-6(3)9/h6,9H,1,4H2,2-3H3,(H,8,10) | | InChIKey | OKPYIWASQZGASP-UHFFFAOYSA-N | | SMILES | CC(O)CNC(=O)C(C)=C |
| Risk Statements | 36/37/38 | | Safety Statements | 26-36/37/39 | | WGK Germany | 3 | | HS Code | 2924297099 | | Storage Class | 11 - Combustible Solids |
| | N-(2-HYDROXYPROPYL)METHACRYLAMIDE Usage And Synthesis |
| Description | N-(2-hydroxypropyl)methacrylamide (HPMA) is an important hydrophilic monomer. Due to the non-toxic, non-immunogenic properties and prolonged circulation time of both its homopolymers and copolymers, it is widely employed in the preparation of PHPMA copolymers (a polymer-drug conjugate) for use in the biopharmaceutical industry. For instance, poly(HPMA-co-MA-GFLG-doxorubicin) represents the first intravenous tumour-targeting polymeric prodrug to enter clinical trials. HPMA polymers and copolymers are also employed in the fabrication of biocompatible medical materials such as hydrogels[1]. | | Uses | Monomers to synthesize biocompetible polymers and copolymers for drug carriers, protein conjugates and hydrogels in biomedical applications. | | in vivo | At 5 mg/kg body weight drug equivalent dose, all N-(2-Hydroxypropyl)methacrylamide copolymer-drug conjugates which contained lysosomally degradable side chains shows significant in vivo antileishmanial activity (>99% inhibition)[1]. | | References | [1] NGUYEN N H, RODRIGUEZ-EMMENEGGER C, BRYNDA E, et al. SET-LRP of N-(2-hydroxypropyl)methacrylamide in H2O†[J]. Polymer Chemistry, 2013, 8: 2424-2427. DOI:10.1039/C3PY00220A. |
| | N-(2-HYDROXYPROPYL)METHACRYLAMIDE Preparation Products And Raw materials |
|